A2B adenosine receptor dampens hypoxia-induced vascular leak.
Extracellular adenosine has been implicated in adaptation to hypoxia and previous studies demonstrated a central role in vascular responses. Here, we examined the contribution of individual adenosine receptors (ARs: A1AR/A2AAR/A2BAR/A3AR) to vascular leak induced by hypoxia. Initial profiling studies revealed that siRNA-mediated repression of the A2BAR selectively increased endothelial leak in response to hypoxia in vitro. In parallel, vascular permeability was significantly increased in vascular organs of A2BAR(-/-)-mice subjected to ambient hypoxia (8% oxygen, 4 hours; eg, lung: 2.1 +/- 0.12-fold increase). By contrast, hypoxia-induced vascular leak was not accentuated in A1AR(-/-)-, A2AAR(-/-)-, or A3AR(-/-)-deficient mice, suggesting a degree of specificity for the A2BAR. Further studies in wild type mice revealed that the selective A2BAR antagonist PSB1115 resulted in profound increases in hypoxia-associated vascular leakage while A2BAR agonist (BAY60-6583 [2-[6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)-. phenyl]pyridin-2-ylsulfanyl]acetamide]) treatment was associated with almost complete reversal of hypoxia-induced vascular leakage (eg, lung: 2.0 +/- 0.21-fold reduction). Studies in bone marrow chimeric A2BAR mice suggested a predominant role of vascular A2BARs in this response, while hypoxia-associated increases in tissue neutrophils were, at least in part, mediated by A2BAR expressing hematopoietic cells. Taken together, these studies provide pharmacologic and genetic evidence for vascular A2BAR signaling as central control point of hypoxia-associated vascular leak.
Eckle
Tobias
T
Departments of Anesthesiology and Intensive Care , Tübingen University Hospital, Tübingen, Germany.
Faigle
Marion
M
Grenz
Almut
A
Laucher
Stefanie
S
Thompson
Linda F
LF
Eltzschig
Holger K
HK
D000241:Adenosine / Q000494:pharmacology / Q000502:physiology; D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D001483:Base Sequence; D002199:Capillary Permeability / Q000502:physiology*; D002463:Cell Membrane Permeability / Q000502:physiology; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000166:cytology / Q000502:physiology*; D006801:Humans; D000860:Hypoxia / Q000503:physiopathology* / Q000517:prevention & control; D051379:Mice; D018345:Mice, Knockout; D008833:Microcirculation; D008969:Molecular Sequence Data; D034741:RNA, Small Interfering / Q000235:genetics; D043704:Receptor, Adenosine A2B / Q000172:deficiency / Q000235:genetics* / Q000502:physiology; D014970:Xanthines / Q000494:pharmacology
C518874:1-propyl-8-(4-sulfophenyl)xanthine; D058917:Adenosine A2 Receptor Antagonists; D034741:RNA, Small Interfering; D043704:Receptor, Adenosine A2B; D014970:Xanthines; D000241:Adenosine